The superdisintegrants market size is projected to reach US$ 0.89 billion by 2031 from US$ 0.50 billion in 2023. The market is expected to register a CAGR of 7.60% during 2023–2031. Growing emphasis on adopting novel drug delivery systems is likely to remain a key trend in the market.
The market is expected to grow due to the growing acceptance of generic medications and the growing use of oral disintegrating solid dosage forms worldwide. North America holds the major market share for superdisintegrants. The largest market for superdisintegrants was in the US, and this market is anticipated to expand due to factors like the rise in superdisintegrant varieties, manufacturers producing more pharmaceuticals, the rise in chronic illness cases, and more. The market is anticipated to expand in Canada and Mexico due to increased government initiatives about pharmaceuticals. Due to the increasing organic and inorganic activities of the companies in the superdisintegrants market, the market in Mexico is anticipated to grow faster.
Generic medications are qualitative and quantitative mixtures of active ingredients whose bioequivalency has been proven through appropriate bioavailability testing. Across the globe, generic drug acceptance and adoption are primarily driven by cost efficiency. Additionally, as oral disintegrating medications become more popular, superdisintegrants will likely be used in generic medications. This will eventually propel the growth of the global superdisintegrants market throughout the forecast period. The expanding healthcare sector in Asia Pacific's developing nations allows big market players to grow their companies. Furthermore, the region's medicine consumption is projected to rise due to the large patient population and rising prevalence of chronic conditions in emerging nations. As a result, the region's expanding healthcare industry is expected to stimulate the market and offer significant growth opportunities to market participants throughout the forecast period.
There is an exponential increase in the prevalence of chronic diseases worldwide. Several factors such as the spread of bacteria, viruses, parasites, genetic disorders, a sedentary lifestyle, poor dietary habits, etc. contribute to increase in prevalence of chronic diseases. Solid dosage forms are becoming more widely used in treating diseases due to the exponential rise in disease prevalence. For instance, the World Health Organization (WHO) states that the most significant cause of death worldwide is cardiovascular disease (CVD). An estimated 17.9 million deaths worldwide in 2019 were attributed to CVDs, accounting for 32% of all deaths. Thus, an upsurge in the prevalence of chronic diseases is likely to drive the demand for products and boost market growth.
Throughout the forecast period, the range of advantages provided by superdisintegrants will probably increase due to ongoing research and development efforts carried out by significant companies and research institutions. Additionally, several pharmaceutical companies' new product launches can be attributed to the growing popularity of orally disintegrating tablets. For instance, in December 2021, the FDA approved the use of oral disintegrating glycopyrrolate tablets to treat peptic ulcers and reduce their symptoms.
Key segments that contributed to the derivation of the superdisintegrants market analysis are type, formulation and therapeutic area.
The geographic scope of the superdisintegrants market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
The market for superdisintegrants in the US holds the largest share among the countries of North America. Regarding pharmaceutical R&D spending, the US leads the globe, with Europe and Asia closely behind. The National Center for Science and Engineering Statistics estimates that academic institutions spent US$ 8.0 billion more on research and development in 2022 than in 2021, for a total of US$ 97.8 billion. Federally funded R&D expenses made up US$ 4.9 billion of the overall increase. Universities spent US$ 2.1 billion more on R&D (institution funds) in 2022 than in 2021, while US$ 587 million more was spent on R&D by businesses.
The regional trends and factors influencing the Superdisintegrants Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Superdisintegrants Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 0.50 Billion |
| Market Size by 2031 | US$ 0.89 Billion |
| Global CAGR (2023 - 2031) | 7.60% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Superdisintegrants Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Superdisintegrants Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The superdisintegrants market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the superdisintegrants market are listed below:
The “Superdisintegrants Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
North America dominated the superdisintegrants market in 2023
Key factors driving the market are the growing adoption of orally disintegrating drugs and the increasing acceptability of generic drugs.
Growing emphasis on adopting novel drug delivery systems is likely to remain a key trend in the market.
Ashland, Asahi Kasei Corporation, Avantor, Inc, BASF SE, Corel Pharma Chem, Dow DuPont Inc., DFE Pharma, JRS Pharma, MERCK KGAA, and Roquette Frères
The market is expected to register a CAGR of 7.6% during 2023–2031.